Pharma Mar (OTCMKTS:PHMMF) Shares Shorted: Short Interest Up 168.3% in September

Pharma Mar (OTCMKTS:PHMMF) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totaling 23,296 shares, a growth of 168.3% from the August 31st total of 8,682 shares. Based on an average daily volume of 1 shares, the days-to-cover ratio is currently 23,296.0 days. Approximately 0.1% of the company’s shares are sold short.

Pharma Mar Price Performance

Shares of OTCMKTS PHMMF opened at $94.60 on Tuesday. The company has a current ratio of 3.02, a quick ratio of 2.44 and a debt-to-equity ratio of 0.14. The company has a 50-day moving average price of $90.59 and a 200-day moving average price of $94.44. Pharma Mar has a 1 year low of $77.41 and a 1 year high of $110.40.

Analysts Set New Price Targets

Several equities analysts have issued reports on the stock. Zacks Research raised shares of Pharma Mar to a “hold” rating in a research note on Monday, June 15th. Chardan Capital raised Pharma Mar to a “strong-buy” rating in a research note on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, Pharma Mar currently has a consensus rating of “Buy”.

About Pharma Mar

Pharma Mar, SA is a Spanish biopharmaceutical company focused on discovering, developing and commercializing medicines derived from marine organisms. The company specializes primarily in oncology, using compounds identified from marine invertebrates and microorganisms as the basis for treatments targeting difficult-to-treat cancers.

Its principal products include Yondelis (trabectedin), which is used in certain markets to treat advanced soft-tissue sarcoma and relapsed ovarian cancer, and Zepzelca (lurbinectedin), an anticancer therapy for metastatic small-cell lung cancer that received accelerated approval in the United States.